Table 3. Clinical parameters of patients with testosterone deficiency syndrome who did not undergo testosterone replacement therapy (control group, n=52).
| Parameter | Baseline | After 8 months | p-value |
|---|---|---|---|
| BMI (kg/m2) | 26.3±3.1 | 26.2±2.6 | 0.219 |
| PSA (ng/mL) | 0.9±1.2 | 0.9±1.1 | 0.477 |
| Prostate volume (mL) | 22.9±7.2 | 22.8±9.1 | 0.549 |
| Hemoglobin (g/dL) | 12.4±1.3 | 12.3±1.2 | 0.491 |
| Hematocrit (%) | 36.6±4.1 | 36.5±3.7 | 0.573 |
| Qmax (mL/s) | 14.1±6.1 | 15.9±5.6 | 0.117 |
| PVR (mL) | 14.6±9.5 | 13.7±8.4 | 0.170 |
| Total testosterone (ng/mL) | 2.6±0.7 | 2.7±0.5 | 0.146 |
| IIEF-5 score | 20.6±4.3 | 21.2±4.6 | 0.172 |
| AMS score | 39.6±7.4 | 39.1±8.1 | 0.324 |
| BDI score | 27.2±5.3 | 26.2±6.4 | 0.139 |
| K-MMSE score | 23.9±4.6 | 23.3±5.2 | 0.248 |
BMI: body mass index, PSA: prostate-specific antigen, Qmax: maximal urinary flow rate, PVR: postvoid residual volume, IIEF-5: 5-item version of the International Index of Erectile Function questionnaire, AMS: Aging Males' Symptoms, BDI: Beck Depression Inventory, K-MMSE: Korean Mini-Mental State Examination.